Physician profile
Gina M Devine
NPI 1760681126
$1,311.45
in general payments reported to CMS, 2019-2025
12 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $12.99 · 2023: $180 · 2024: $329 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.94 | 2021-2025 | |
| Glaxosmithkline, LLC. | $276.00 | 2021-2023 | Arexvy, Shingrix |
| Boston Scientific Corporation | $142.22 | 2025 | Intracept |
| Relievant Medsystems, INC. | $97.47 | 2021 | |
| Pfizer INC. | $44.40 | 2021-2024 | |
| Lilly USA, LLC | $43.11 | 2022-2024 | Mounjaro |
| Eisai INC. | $41.03 | 2024-2025 | |
| Novo Nordisk INC | $30.31 | 2024 | Wegovy |
| Inspire Medical Systems, INC. | $28.69 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $25.00 | 2024 | Nexletol |
| Exact Sciences Corporation | $19.74 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $15.54 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.